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Abstract: This study was performed to determine the body fat percentage, fat distribution and plasma lipid-cholesterol levels of
patients with multiple sclerosis (MS). We compared the body fat percentage, distribution and lipid profile in 22 patients with
definitive diagnosis of MS and age and height matched 16 healthy control subjects on normal diets. Poser criteria was used to
determine the MS diagnosis. Body fat percentage and distribution were evaluated anthropometrically by measuring skin fold
thickness from 7 different reference points of the body. The parameters of the body composition were obtained by using the
equations of Durning, Womersly and Siri. Body fat distribution was calculated by using Mueller’s formulation. The plasma levels of
total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), very low density
lipoprotein-cholesterol (VLDL-C) and triglycerides were measured spectrophotometrically in patients and healthy volunteers. The
mean body fat percentage of male MS patients was significantly the lower than in the male controls (P < 0.05). Body mass index
and lean body mass of MS patients did not differ from the controls of either sex. The ratio of central to peripheral body fat was
lower in all MS patients. Although male patients had a lower ratio, the difference with the control group was not statistically
significant. The ratio of upper to lower body fat in male patients was significantly higher than in the controls (P < 0.05). This
difference was not present in the female population. Mean plasma total cholesterol levels were slightly higher in MS patients than
in healthy volunteers, but this was not significant. Mean plasma HDL-C and LDL-C levels of the MS patients were not statistically
different from the values of the controls. The levels of plasma VLDL-C and triglycerides of patients were significantly higher than
the levels of healthy subjects (P < 0.05). Our results show that total subcutaneous fat stores of the body were diminished in male
MS patients. Truncal and lower body fat of MS patients was reduced and upper body fat was increased when compared to the
controls. Plasma levels of VLDL-C and triglycerides were also found to be higher in MS patients. It is considered that lipid metabolism
can be influenced by MS. Further studies are needed to investigate how the fat storage process changes and to understand the
importance of alterations in the plasma lipid profile in the course of MS.
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Introduction
Multiple sclerosis (MS) is a major demyelinating
disease, with an unknown etiology, affecting white
matter of the central nervous system and medulla spinalis
(1,2). Many factors have been associated with its
prognosis (3-14). Among these factors, feeding habits
and body composition are especially important and these
topics have been studied recently (6,7,14-19).
The negative effects of excessive animal fat
consumption in MS patients were first determined by

Swank et al. in 1950 (5-7). A patient was also reported
who had a disorder of the fatty acid metabolism similar
to that of MS (20). It has been thought that MS can alter
the lipid metabolism and body fat storage and distribution
(21-26). Inflammation in chronic illness is generally
related with the alteration in body composition including
weight loss, decreases in total body fat and increases in
central fat deposition (27,28). The increasing production
of interleukin-1 can at least in part be responsible for this
kind of body composition alteration. Interleukin-1 might
increase plasma triglycerides and LDL and cause abnormal

43

Body Fat Distribution and Plasma Lipid Profiles of Patients with Multiple Sclerosis

fat distribution by inhibiting lipoprotein lipase activity
(27). It is also known that central fat deposition is
associated with the atherogenic plasma lipid profile,
including increases in LDL and triglycerides and decreases
in HDL (29,30). Additionally, centripetal fat deposition
and increases in total body fat negatively affect general
health (21,31-36). This study was designed to assess the
importance of abnormal fat distribution and deposition
and plasma lipid profile changes in MS patients.

Materials and Methods
In this study, to determine the body fat percentage,
distribution and plasma levels of total cholesterol,
triglycerides, HDL-C, LDL-C and VLDL-C were evaluated in
MS patients and healthy subjects of similar ages. Poser
criteria were used by diagnosing definitive MS and the
motor capacity of the patients was evaluated by Kurtzke
expanded disability status scale (EDSS), in a range from
0.5 to 5.5. Diet in both groups was similar and contained
normal amounts of animal fats. All persons in both
groups were not taking drugs and were not suffering
from any metabolic disorder that might affect plasma
levels of lipid-cholesterol and body fat stores.
Body fat percentage and distribution were evaluated
anthropometrically by measuring skin fold thickness from
7 different reference points of the body. The parameters
of the body composition were obtained by using the
equations of Durning, Womersly and Siri. Body fat
distribution was calculated by using Mueller’s
formulation. Calibrated balance scales with divisions of
100 g and 0.5 cm were used for weight and height
measurements. Body mass index (kg/m2) was calculated
by dividing the body weight by the square of the
measured height. On all subjects, 7 skinfold
measurements were obtained from the left side of the
body with a skinfold caliper (Servier, France). All the
measurements were made by the same physician (SÇ).
Skinfold thickness measurements were performed on
standard anthropometrical reference points such as the
biceps, triceps, subscapular, abdomen, suprailiac, thigh
and calf. Using the equations of Durning and Womersly,
body density estimations were derived from skinfold
thickness measurements. Parameters obtained by using
the algorithm of the sum of 4 skinfold thickness
measurements (biceps + triceps + subscapular +
suprailiac) were sex specific (35-40). The formula of
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body density for males was 1.1631- (0.0632 x log Σ 4Sf)
and for females. It was 1.1599 – (0.0717 x log Σ 4Sf).
The equation given by Siri was used to estimate body fat
percentage from the 4 skinfold thickness measurements.
The Siri equation for estimation of body fat percentage is
[4.95/(body density x 4.50)] x 100 (35). To evaluate the
subcutaneous truncal fat mass, the following equation of
Mueller was used: the ratio of central to peripheral fat
distribution: [(subscapular + suprailiac + abdomen) /
(biceps + triceps + thigh + calf)]. To estimate the upper
body fat deposition, the ratio of upper to lower body
skinfold thickness measurements was calculated by using
the following equation; the ratio of upper to lower body
fat distribution: [(biceps + triceps + subscapular) /
(suprailiac + thigh + calf)] (22).
Blood samples from all subjects were collected from
the antecubital vein between 08.00 and 10.00 hours.
Plasma was separated by centrifuging blood at 4000 rpm
for 15 min. Plasma total cholesterol level was measured
by using the enzymatic end point method (Randox CH
201 kit). Plasma triglycerides were determined by the
GPO-PAP method (Randox TR 212). Plasma HDL-C levels
were assayed by the fully enzymatic cholorimetric method
(Randox CH 2655). Plasma LDL-C and VLDL-C levels
were calculated by using the Freidwold formula. An
Olympus AV 800 spectrophotometer (Germany) was used
for all lipid assays.
Statistical Analyses: Data are expressed as mean ±
standard deviation of mean. The Mann-Whitney U test
was used for statistical analyses.

Results
The mean ages of the male and female patients (n:
12/10) were 38.4 ± 2.6 and 35.7 ± 4.7 years,
respectively. The mean ages of the healthy male and
female volunteers (n: 8/8) were 39.3 ± 3.0 and 41.0 ±
4.1 years, respectively. The differences between the
mean ages of males and females in both groups were not
statistically significant. The mean height of patients was
not statistically different from the healthy subjects of
both sexes. The mean weight and body mass index (BMI)
of male MS patients were found to be slightly lower than
those of male healthy volunteers, which was not
significant. Mean weight and body mass index were
slightly higher in female patients compared to female
controls, but the difference was not statistically
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significant (Table 1). Mean height, weight and body mass
index of MS patients were not significantly different from
those of the control subjects (Table 1). The body fat
percentage of male MS patients was significantly lower
when compared to healthy male subjects (P < 0.05). In
females there was no significant difference in body fat
percentage between MS patients and healthy volunteers.
The lean body mass of MS patients and healthy volunteers
were similar in both sexes. The ratio of central to
peripheral body fat distribution of female MS patients
was significantly lower than that of the female controls (P
< 0.05), but the same observation did not apply to the
males. The ratio of upper to lower body fat distribution
was significantly higher in male MS patients (P < 0.05).
This parameter in female MS patients was slightly lower,

but not significantly different from that in healthy
subjects (Table 1). Mean duration of disease was 8.2 ±
3.1 years.
Mean plasma levels of total cholesterol, triglycerides,
HDL-C, LDL-C and VLDL-C of progressive MS patients and
healthy volunteers are given in Table 2.
The plasma levels of triglycerides and VLDL-C levels
were significantly higher in progressive MS patients than
those of the controls (Table 2). The mean plasma total
cholesterol level of patients was found to be slightly
higher in the patients group, but differences between the
patients and controls were not statistically significant.
Plasma HDL-C and VLDL-C levels were not different from
those of the controls.

Table 1. Some anthropometric characteristics of MS patients and control subjects. (Mean values ± standard deviation of means)

Variable

Patient Group (n: 22)

Control Group (n: 16)

Male

Female

Male

Female

12

10

8

8

Statistical Analyses
In Males

In Females

Age (years)

38.42 ± 2.60

35.70 ± 4.7

39.3 ± 3.0

41.0 ± 4.1

NS

NS

Height (cm)

170.17 ± 5.71

157.60 ± 1.72

171.00 ± 9.54

NS

159.14 ± 6.79

NS

Weight (kg)

69.00 ± 12.44

61.80 ± 11.10

69.14 ± 12.23

58.57 ± 9.13

NS

NS

BMI (kg/m2)

23.83 ± 3.77

24.85 ± 4.18

23.48 ± 2.26

23.63 ± 2.97

NS

NS

Body Fat Percent (%)

13.33 ± 3.84

21.89 ± 3.86

17.96 ± 1.15

21.81 ± 4.55

P < 0.05

NS

Lean Body Mass (kg)

59.63 ± 10.16

47.94 ± 6.89

58.05 ± 7.14

45.78 ± 6.86

NS

NS

0.87 ± 0.20

0.57 ± 0.15

1.00 ± 0.17

0.87 ± 0.15

NS

P < 0.05

1.02 ± 0.22

0.83 ± 0.22

0.82 ± 0.20

0.65 ± 0.18

P < 0.05

NS

Central/ Peripheral
Body Fat
Upper/Lower
Body Fat

Table 2. Plasma lipid profiles of progressive MS patients and healthy controls (Total cholesterol: T.Chol, Triglycerides: Trigly).

Control Group

Patient Group

Male

Female

T.Chol (mg/dl)

172.50 ± 35.38

177.25 ± 21.53

206.40 ± 20.43

192.33 ± 30.06

NS

NS

Trigly (mg/dl)

118.00 ± 27.93

101.00 ± 54.10

151.40 ± 37.90

241.00 ± 121.50

P < 0.05

P < 0.05

HDL-C (mg/dl)

64.00 ± 16.43

51.75 ± 14.22

57.60 ± 4.93

51.67 ± 8.04

NS

NS

LDL-C (mg/dl)

87.50 ± 23.87

101.25 ± 11.03

118.60 ± 19.03

87.67 ± 17.00

NS

NS

VLDL-C (mg/dl)

21.00 ± 7.62

24.25 ± 10.87

30.30 ± 7.40

48.17 ± 25.34

P < 0.05

P < 0.05

1.36 ± 0.36

1.95 ± 0.32

2.05 ± 0.28

1.69 ± 0.30

P < 0.05

NS

LDL-C/HDL-C

Male

Statistical Analyses
Female

In Male

In Female
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Discussion
Our results indicated that the mean body fat
percentage of male MS patients, except for female
patients, were significantly lower and the mean plasma
levels of triglycerides and VLDL-C were found to be
significantly higher than those of the controls (P < 0.05).
These findings support the consideration that lipid
metabolism and body fat mass changed in MS disease.
It is widely accepted that relative excess truncal and
upper body fat is associated with atherosclerotic
cardiovascular disease (29). Changes in body composition
generally occur along with the activation of the immune
system by chronic illness characterized by tissue injury
and inflammation (29). Inflammation in chronic illness
leads to the release of cytokines such as interleukin-1,
and tumor necrosis factors responsible for alterations in
body composition including weight loss, decreases in total
body fat and increases in central fat deposition (27,28).
The effect of interleukin-1 on abnormal fat distribution
can be related with the inhibitory effect of lipoprotein
lipase activity leading to increased levels of plasma
triglycerides and LDL (27). It is also known that central
fat deposition is associated with atherogenic plasma lipid
profile including increases in LDL, triglycerides and
decreases in HDL (29,30). The loss of body weight and
fat in chronic illness can be strongly related with the
lipolyses and connective tissue remodelity as well as an
increasing of the protein turnover effect of the tumor
necrosis factor (27). However, interleukin-1 beta also has
an anabolic effect on connecting and visceral muscle
tissue. Its anabolic effect can be related with stimulation
of the production of platelet-derived growth factor,
which cause a proliferation of fibroblasts and muscle cells
(27). In other words, immobility is considered a causal
factor for decreases in muscle mass (13,14,26). Formica
et al. reported that nonambulatory patients with MS had
reduced fat-free mass. It was emphasized that deficits in
fat-free mass were associated with the severity of MS.
The decrease in fat-free mass can be related to the
development of the skeletal muscle atrophy in this illness.
According to this hypothesis, MS leads to weakness
resulting from atrophy of the skeletal muscles due to the
reduction in total mitochondrial content per volume of
contractile machinery (31). In this study, there was no
significant difference in lean body mass between MS
patients and control subjects. These findings were the
opposite of the results expected.
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Our results show that total subcutaneous fat stores of
the body were diminished in male MS patients and
truncal-lower body fat was reduced and upper body fat
was increased when compared to the controls. These
findings contradicted our expectations, as diminished
daily motor activity is regarded as a predisposing factor
to total body and truncal fat accumulation. However,
Petejan et al. reported that the body fat percentage of MS
patients was not lower than the normal ranges of a
healthy population.
Some authors emphasized that lipid metabolism
abnormalities are not only limited to the myelin sheet, but
changes that affect the plasma lipid profile can also be
seen in MS patients (8,15,19,20,41-49). In a limited
number of studies, it has been suggested that the
alteration in the plasma lipid profile is a causative factor
for the progression of MS by interfering with the
formation of MS plaques (6,7,12,14,41,46). The
changes in plasma lipid profile can be considered the
stimulating factor for the development of neurovascular
pathologies, which are shown by near by MS plaques (1214,19,42,45,46).
In previous studies, it has been shown that diets rich
in saturated fat are strongly associated with the
progression of MS (1,3,5-8,10,17,43,47). It was
reported that a diet poor in animal fat, but rich in
essential fatty acids was useful for preventing the
progress of MS (5-8,13-15,18,41,47,49). Differences in
plasma lipid profiles between MS patients and controls
obtained in this study are not associated with the
difference between the diet of MS patients and healthy
controls because the diet compositions were similar in
both groups. The other reason for the differences in
plasma lipid profiles may be the difference in intensity
and/or duration of motor activity between the 2 groups.
It is known that lipid catabolism increases with metabolic
activity severity due to physical activity, but we have not
encountered any study evaluating the relationship
between the alterations in plasma lipid and decreased
motor activity in MS. The third reason for the changes in
the plasma lipid profile of progressive MS patients may be
due to alterations in the lipid metabolism (46). Some
metabolic changes that can affect the lipid metabolism
were reported in various studies (19,20,46). For
example, elevated cerebrospinal fluid sorbitol and
fructose concentrations, increases in plasma fatty acid
levels and augmented plasma glutamic acid levels were
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shown in MS (8,10,14,16,41). It is considered that these
variations caused the increase in the NADPH / NADP ratio.
NADPH is used for the biosynthesis of acetate, which is
the precursor of both cholesterol and triglycerides. It is
known that when a low amount of fat is taken in the diet,
fatty acid biosynthesis is increased by excessive
consumption of NADPH (48). Additionally, it was
indicated that the main essential fatty acid, linoleic acid,
fell in the red and white blood cells of MS patients
(13,14). The other source of elevated plasma levels of
triglycerides, VLDL-C and cholesterol, can be the cause of
the demyelinization of MS plaques. Studies on lipid
metabolism in MS patients have shown that some
alterations in lipid content in the myeline cover of neurons
exist (12-14,19,20,45,46). In the demyelination foci,
total cholesterol and phospholipid content of myelin cover
decreased (14). It was demonstrated that an elevated
cholesterol concentration in cerebrospinal fluid in MS was
considered the best indicator for demyelination in MS
plaques (14,19). It was suggested that the activation of
lipotrophin-endorphin
metabolism-related
lipase

stimulation was responsible for the release of lipid
contents of MS plaques (13,14). In additional,
macrophage activation due to the existing reactive
antibodies against auxiliary lipids (cholesterol, lecithin and
phospholipid in galactocerebrosides and gangliosides)
forms the other causal factor for the release the of the
lipid content of demyelination foci (14,49). These
preliminary reports indicate that alterations in the lipid
metabolism could exist in MS patients.
Further studies are needed to investigate how the fat
storage process changes and to understand the
importance of alterations in the plasma lipid profile in the
course of MS.
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